| 000 | 01511 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513162209.0 | ||
| 264 | 0 | _c19990326 | |
| 008 | 199903s 0 0 eng d | ||
| 022 | _a0031-6970 | ||
| 024 | 7 |
_a10.1007/s002280050537 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRaslová, K | |
| 245 | 0 | 0 |
_aCiprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical pharmacology _c |
||
| 300 |
_a697-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 |
_aArteriosclerosis _xgenetics |
| 650 | 0 | 4 |
_aClofibric Acid _xanalogs & derivatives |
| 650 | 0 | 4 | _aDNA Damage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFibric Acids |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypolipidemic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aKinetics |
| 650 | 0 | 4 |
_aLipoproteins _xgenetics |
| 650 | 0 | 4 |
_aLipoproteins, HDL _xblood |
| 650 | 0 | 4 |
_aLipoproteins, LDL _xblood |
| 650 | 0 | 4 |
_aLymphocytes _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aOxidation-Reduction |
| 650 | 0 | 4 | _aPhenotype |
| 700 | 1 | _aDobiásová, M | |
| 700 | 1 | _aNagyová, A | |
| 700 | 1 | _aFábry, R | |
| 700 | 1 | _aRauchová, H | |
| 700 | 1 | _aDusinská, M | |
| 773 | 0 |
_tEuropean journal of clinical pharmacology _gvol. 54 _gno. 9-10 _gp. 697-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s002280050537 _zAvailable from publisher's website |
| 999 |
_c9885227 _d9885227 |
||